Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation

Exclusion Criteria

• •Significant history of hypersensitivity to eslicarbazepine, oxcarbazepine, carbamazepine or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
• •Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
• •History of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability, including but not limited to cholecystectomy
• •Presence of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic disease
• •Presence of significant heart disease or disorder according to ECG
• •Presence or history of significant central nervous system disorder like convulsion or depression
• •Participation in any previous study with eslicarbazepine acetate
• •Females who are pregnant according to a positive serum pregnancy test or are lactating
• •Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the study
• •Use of systemic contraceptives (oral, implant, etc.) in the previous 14 days before day 1 of this study and until study completion.
• •Use of systemic contraceptives (injections) and hormonal replacement therapy in the previous 13 weeks before day 1 of this study and until study completion
• •Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
• •Any clinically significant illness in the previous 28 days before day 1 of this study
• •Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampin), in the previous 28 days before Day 1 of this study
• •Participation in another clinical trial or donation of 50 mL or more of blood in the previous 28 days before day 1 of this study
• •Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
• •Positive urine screening of drugs of abuse (drugs listing is presented in section 6.1.1.4)
• •Any history of tuberculosis and/or prophylaxis for tuberculosis
• •Positive results to HIV, HBsAg or anti-HCV tests